|
Name |
Xylarenone E
|
| Molecular Formula | C26H40O8 | |
| IUPAC Name* |
[(1aR,4R,7S,7aR,7bR)-1a-(3-hydroxyprop-1-en-2-yl)-7,7a-dimethyl-2-oxo-5,6,7,7b-tetrahydro-4H-naphtho[1,2-b]oxiren-4-yl] 2,7-dihydroxy-2-(hydroxymethyl)-4,6-dimethyloctanoate
|
|
| SMILES |
C[C@H]1CC[C@H](C2=CC(=O)[C@]3([C@@H]([C@]12C)O3)C(=C)CO)OC(=O)C(CC(C)CC(C)C(C)O)(CO)O
|
|
| InChI |
InChI=1S/C26H40O8/c1-14(9-15(2)18(5)29)11-25(32,13-28)23(31)33-20-8-7-16(3)24(6)19(20)10-21(30)26(17(4)12-27)22(24)34-26/h10,14-16,18,20,22,27-29,32H,4,7-9,11-13H2,1-3,5-6H3/t14?,15?,16-,18?,20+,22+,24+,25?,26-/m0/s1
|
|
| InChIKey |
SYBSGEKEVRNWDG-DBCRVZMNSA-N
|
|
| Synonyms |
Xylarenone E; CHEBI:69734; CHEMBL1813185; Q27138079
|
|
| CAS | NA | |
| PubChem CID | 53360339 | |
| ChEMBL ID | CHEMBL1813185 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 480.6 | ALogp: | 1.8 |
| HBD: | 4 | HBA: | 8 |
| Rotatable Bonds: | 11 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 137.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 34 | QED Weighted: | 0.212 |
| Caco-2 Permeability: | -5.101 | MDCK Permeability: | 0.00003160 |
| Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.617 |
| Human Intestinal Absorption (HIA): | 0.104 | 20% Bioavailability (F20%): | 0.009 |
| 30% Bioavailability (F30%): | 0.009 |
| Blood-Brain-Barrier Penetration (BBB): | 0.575 | Plasma Protein Binding (PPB): | 44.22% |
| Volume Distribution (VD): | 0.433 | Fu: | 57.04% |
| CYP1A2-inhibitor: | 0.006 | CYP1A2-substrate: | 0.111 |
| CYP2C19-inhibitor: | 0.011 | CYP2C19-substrate: | 0.796 |
| CYP2C9-inhibitor: | 0.008 | CYP2C9-substrate: | 0.043 |
| CYP2D6-inhibitor: | 0.001 | CYP2D6-substrate: | 0.045 |
| CYP3A4-inhibitor: | 0.367 | CYP3A4-substrate: | 0.791 |
| Clearance (CL): | 2.684 | Half-life (T1/2): | 0.935 |
| hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.165 |
| Drug-inuced Liver Injury (DILI): | 0.842 | AMES Toxicity: | 0.901 |
| Rat Oral Acute Toxicity: | 0.438 | Maximum Recommended Daily Dose: | 0.361 |
| Skin Sensitization: | 0.916 | Carcinogencity: | 0.269 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.031 |
| Respiratory Toxicity: | 0.926 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002779 | ![]() |
0.835 | D03SXE | ![]() |
0.230 | ||
| ENC002770 | ![]() |
0.648 | D02RQU | ![]() |
0.221 | ||
| ENC002482 | ![]() |
0.484 | D08PIQ | ![]() |
0.216 | ||
| ENC005060 | ![]() |
0.321 | D0F7NQ | ![]() |
0.213 | ||
| ENC002137 | ![]() |
0.288 | D0IT2G | ![]() |
0.213 | ||
| ENC003665 | ![]() |
0.275 | D07DVK | ![]() |
0.213 | ||
| ENC002888 | ![]() |
0.270 | D03IKT | ![]() |
0.213 | ||
| ENC002887 | ![]() |
0.270 | D0CW1P | ![]() |
0.213 | ||
| ENC005889 | ![]() |
0.252 | D0E9KA | ![]() |
0.211 | ||
| ENC004127 | ![]() |
0.248 | D0I5DS | ![]() |
0.207 | ||